Inclusion Criteria:  Ability to voluntarily provide written informed consent. Documented diagnosis per World Health Organization (WHO) 2016 criteria of BCR-ABL negative myeloproliferative neoplasms (MPN). Documented MPN transformation to accelerated phase (AP) or blast phase (BP) without prior blast reduction therapy for their AP/BP disease. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Adequate organ function. Must practice at least one reliable method of birth-control starting at least on cycle 1 day 1 until at least 90 days after the last dose of study drug. Female participants of childbearing potential must have a negative serum pregnancy test within 14 days prior to cycle 1 day 1.  Exclusion Criteria:  History of allogeneic stem cell transplant for MPN. Previous treatment with venetoclax, navitoclax, azacytidine or other hypomethylating agents (HMA). White blood cell count >25 x 10^9/L. Current enrollment in another interventional study. Presence of any active uncontrolled infection such as bacterial or fungal infections progressing despite adequate antimicrobial treatment. Myocardial infarction in the preceding 3 months. Active human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV) infection. History of active malignancy in the previous 2 years. Any psychiatric illness or social circumstances or significant co-morbid conditions that may compromise study participation. Pregnant or breastfeeding women. Patients with known central nervous system (CNS) involvement with acute myeloid leukemia (AML) or CNS extramedullary hematopoiesis. Patients with t (15;17) Patients who have received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment. Active COVID-19 infection. History of prior blast-reduction therapy for AP/BP-MPN. Preceding history MDS, chronic myelomonocytic leukemia (CMML), and other myelodysplastic syndromes (MDS)/MPN overlap syndromes.